Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142357 | 0.86 | POLB (0.57) | TMPRSS4EPHX2P2RX1HDAC3HDAC1 | |
| SCHEMBL21849248 | 0.85 | ALDH1A1 (0.49) | TMPRSS4EPHX2MAPTLMNASMN1; SMN2 | |
| SCHEMBL5773763 | 0.84 | MAPT (0.67) | TMPRSS4P2RX1MAPTNR2E1GPR35 | |
| SCHEMBL14520815 | 0.84 | TMPRSS4 (0.52) | TMPRSS4EPHX2P2RX1HDAC3HDAC1 | |
| SCHEMBL5474295 | 0.84 | TMPRSS4 (0.52) | TMPRSS4EPHX2P2RX1HDAC3HDAC1 | |
| SCHEMBL5474298 | 0.84 | TMPRSS4 (0.52) | TMPRSS4EPHX2P2RX1HDAC3HDAC1 | |
| SCHEMBL27757155 | 0.83 | MAPT (0.46) | TMPRSS4EPHX2P2RX1MAPTNR2E1 | |
| SCHEMBL171686 | 0.82 | KMT2A (0.63) | LMNASMN1; SMN2MTNR1AMTNR1BKMT2A | |
| SCHEMBL6011964 | 0.82 | TMPRSS4 (0.53) | TMPRSS4EPHX2P2RX1HDAC3HDAC1 | |
| SCHEMBL5031966 | 0.82 | LMNA (0.56) | TMPRSS4EPHX2P2RX1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | TMPRSS4 1938/4885EPHX2 2525/4885P2RX1 811/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | TMPRSS4 1938/4885EPHX2 2525/4885P2RX1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.